Carl Byrnes
Stock Analyst at Northland Capital Markets
(1.85)
# 2,941
Out of 4,820 analysts
23
Total ratings
37.5%
Success rate
2.99%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $24.74 | +25.33% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $5.75 | +117.39% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $8.89 | +40.61% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $1.29 | +365.12% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.40 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $40 → $25 | $10.33 | +142.01% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $8 | $0.46 | +1,658.24% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $20.78 | +284.99% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $6.94 | +231.41% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $0.96 | +2,400.26% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $1.12 | +178,471.43% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.34 | - | 1 | Sep 27, 2017 |
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $24.74
Upside: +25.33%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $5.75
Upside: +117.39%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $8.89
Upside: +40.61%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $1.29
Upside: +365.12%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.40
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $40 → $25
Current: $10.33
Upside: +142.01%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $8
Current: $0.46
Upside: +1,658.24%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $20.78
Upside: +284.99%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $6.94
Upside: +231.41%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $0.96
Upside: +2,400.26%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $1.12
Upside: +178,471.43%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.34
Upside: -